LITS (Lite Strategy) 12-1 Month Momentum %: -71.66% (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LITS Lite Strategy Inc LITS
22 GF Score
Price $1.10
! 3 Warning Signs
View Full Analysis

What is Lite Strategy 12-1 Month Momentum %?

Lite Strategy LITS +3.76% 22 12-1 Month Momentum % is -71.66% as of Sep. 11, 2026. GuruFocus rates LITS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,357 Biotechnology companies, Lite Strategy ranks worse than 89.98% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-11), Lite Strategy's 12-1 Month Momentum % is -71.66%.

The industry rank for Lite Strategy's 12-1 Month Momentum % or its related term are showing as below:

LITS's 12-1 Month Momentum % is ranked worse than
89.98% of 1357 companies
in the Biotechnology industry
Industry Median: -19.89 vs LITS: -71.66

Lite Strategy  (NAS:LITS) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Lite Strategy 12-1 Month Momentum % Related Terms

LITS vs KYNB, QNCX, IGC: 12-1 Month Momentum % Comparison

For the Biotechnology subindustry, Lite Strategy's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lite Strategy 12-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lite Strategy's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Lite Strategy's 12-1 Month Momentum % falls into.


LITS
22GF Score
Lite Strategy Inc LITS
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lite Strategy  (NAS:LITS) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of -71.66% mean?
Lite Strategy (LITS) has a 12-1 Month Momentum % of -71.66% as of Sep. 11, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Lite Strategy and its competitors. According to the industry distribution chart, Lite Strategy ranks #1221 out of 1357 companies in the Biotechnology industry, placing it in the top 90%.
Is Lite Strategy's 12-1 Month Momentum % too high?
Lite Strategy's current 12-1 Month Momentum % is -71.66%. Based on the distribution chart, Lite Strategy ranks #1221 out of 1357 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lite Strategy has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Lite Strategy's 12-1 Month Momentum % compare to KYNB and QNCX?
According to the Biotechnology industry distribution chart, Lite Strategy ranks #1221 out of 1357 companies for 12-1 Month Momentum %. This places Lite Strategy in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Lite Strategy and its competitors. Lite Strategy's current 12-1 Month Momentum % is -71.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lite Strategy stock overvalued right now?
Lite Strategy (LITS) has a current 12-1 Month Momentum % of -71.66%. The current 12-1 Month Momentum % is -71.66%. Lite Strategy's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Lite Strategy (LITS), the current 12-1 Month Momentum % is -71.66% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lite Strategy Business Description

Other Exchanges 0JW9:UK
Address 9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
22GF Score

Get the complete analysis for LITS

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.10
Price